Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...

Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal...

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) --...

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular...

T-Cell Therapy Market To Reach USD 8.37 Billion By 2027 | Reports and Data New York, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The Global T-Cell Therapy Market is forecast to reach USD 8.37 Billion by 2027, according to a new report by Reports and Data. The T-cell therapy involves...